385 related articles for article (PubMed ID: 29058991)
1. The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients.
Shi Z; Meng Z; Han Y; Cao C; Tan G; Wang L
Lupus; 2018 Apr; 27(4):621-627. PubMed ID: 29058991
[TBL] [Abstract][Full Text] [Related]
2. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus.
Shi ZR; Tan GZ; Meng Z; Yu M; Li KW; Yin J; Wei KH; Luo YJ; Jia SQ; Zhang SJ; Wu J; Mi XB; Wang L
Arthritis Rheumatol; 2015 Jan; 67(1):193-203. PubMed ID: 25307291
[TBL] [Abstract][Full Text] [Related]
3. Plasma galectin-3 levels do not differ in systemic lupus erythematosus patients.
Zhao CN; Mao YM; Liu LN; Wu Q; Dan YL; Pan HF
Int J Rheum Dis; 2019 Oct; 22(10):1820-1824. PubMed ID: 31402566
[TBL] [Abstract][Full Text] [Related]
4. IL-17 in cutaneous lupus erythematosus.
Tanasescu C; Balanescu E; Balanescu P; Olteanu R; Badea C; Grancea C; Vagu C; Bleotu C; Ardeleanu C; Georgescu A
Eur J Intern Med; 2010 Jun; 21(3):202-7. PubMed ID: 20493423
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype.
Peene I; Meheus L; Veys EM; De Keyser F
Ann Rheum Dis; 2002 Dec; 61(12):1090-4. PubMed ID: 12429541
[TBL] [Abstract][Full Text] [Related]
6. Serum galectin-3 level in systemic sclerosis.
Koca SS; Akbas F; Ozgen M; Yolbas S; Ilhan N; Gundogdu B; Isik A
Clin Rheumatol; 2014 Feb; 33(2):215-20. PubMed ID: 23912642
[TBL] [Abstract][Full Text] [Related]
7. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
[TBL] [Abstract][Full Text] [Related]
8. Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus.
Hu FQ; Zhang YP; Yin J; Tang ZQ; Han YF; Shi ZR; Tan GZ; Wang L
Lupus; 2021 Feb; 30(2):315-319. PubMed ID: 33086919
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients.
Nabatian AS; Bashir MM; Wysocka M; Sharma M; Werth VP
Arthritis Res Ther; 2012 Jan; 14(1):R1. PubMed ID: 22217359
[TBL] [Abstract][Full Text] [Related]
10. A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature.
Yildirim Cetin G; Sayar H; Ozkan F; Kurtulus S; Kesici F; Sayarlioglu M
Lupus; 2013 Jul; 22(8):839-46. PubMed ID: 23761100
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
[TBL] [Abstract][Full Text] [Related]
12. Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus.
Hofmann SC; Bosma A; Bruckner-Tuderman L; Vukmanovic-Stejic M; Jury EC; Isenberg DA; Mauri C
J Dermatol Sci; 2013 Jul; 71(1):22-8. PubMed ID: 23664188
[TBL] [Abstract][Full Text] [Related]
13. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
Front Immunol; 2021; 12():775353. PubMed ID: 34868043
[TBL] [Abstract][Full Text] [Related]
14. Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus.
Kalinska-Bienias A; Kowalczyk E; Bienias P; Gala K; Jagielski P; Kowalewski C
Postepy Dermatol Alergol; 2021 Apr; 38(2):274-280. PubMed ID: 34408596
[TBL] [Abstract][Full Text] [Related]
15. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome.
van den Hoogen LL; van Roon JAG; Mertens JS; Wienke J; Lopes AP; de Jager W; Rossato M; Pandit A; Wichers CGK; van Wijk F; Fritsch-Stork RDE; Radstake TRDJ
Ann Rheum Dis; 2018 Dec; 77(12):1810-1814. PubMed ID: 30185417
[TBL] [Abstract][Full Text] [Related]
16. Antilaminin-1 antibodies in cutaneous lupus erythematosus patients.
Caproni M; Antiga E; Cardinali C; Del Bianco E; Fabbri P
Lupus; 2009 Aug; 18(9):858. PubMed ID: 19578114
[No Abstract] [Full Text] [Related]
17. Serum pentraxin 3 in systemic lupus erythematosus: A potential indicator of cutaneous disease activity.
Ismail SA; Awad SM; Gamal RM; Gaber MA; Hussein SM; Hammam N
Lupus; 2023 Jun; 32(7):873-879. PubMed ID: 37183233
[TBL] [Abstract][Full Text] [Related]
18. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus.
Matsuoka N; Fujita Y; Temmoku J; Furuya MY; Asano T; Sato S; Matsumoto H; Kobayashi H; Watanabe H; Suzuki E; Kozuru H; Yastuhashi H; Migita K
PLoS One; 2020; 15(1):e0227069. PubMed ID: 31986153
[TBL] [Abstract][Full Text] [Related]
19. Anti-high mobility group box 1 (anti-HMGB1) antibodies are not related to the occurrence of cutaneous lesions in systemic lupus erythematosus.
Tan G; Zhu N; Shi Z; Meng Z; Yu M; Li K; Yin J; Wei K; Mi X; Wang L
Scand J Rheumatol; 2015; 44(2):150-6. PubMed ID: 25439526
[TBL] [Abstract][Full Text] [Related]
20. The association of anti-annexin1 antibodies with the occurrence of skin lesions in systemic lupus erythematosus.
Meng Z; Shi ZR; Tan GZ; Yin J; Wu J; Mi XB; Wang L
Lupus; 2014 Feb; 23(2):183-7. PubMed ID: 24300781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
